Metastatic melanoma: pretreatment contrast-enhanced CT texture parameters as predictive biomarkers of survival in patients treated with pembrolizumab.

Fiche publication

Date publication

janvier 2019

Journal

European radiology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr HOEFFEL Christine

Tous les auteurs :
Durot C, Mulé S, Soyer P, Marchal A, Grange F, Hoeffel C

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/30645669

Résumé

To determine whether texture analysis features on pretreatment contrast-enhanced computed tomography (CT) images can predict overall survival (OS) and progression-free survival (PFS) in patients with metastatic malignant melanoma (MM) treated with an anti-PD-1 monoclonal antibody, pembrolizumab.